Skip to Content

2 Month Metformin Weight Loss Results: Should You Consider It

2 Month Metformin Weight Loss Results: Should You Consider It

Curious about the 2 Month Metformin Weight Loss Results? Should you consider metformin therapy for weight loss without beign diabetic? Learn more in this article.

Studies have shown that Metformin can help people with obesity who don’t have type 2 diabetes shed some pounds. The amount of weight loss isn’t huge, but it’s enough to make a difference and comes with the bonus of being affordable. Metformin is also popular for being safe over the long haul, with minimal serious side effects, and has other health benefits that don’t involve blood sugar. So far, Metformin stands out because it’s the only weight-loss drug that has shown it can keep the pounds off over time.

Therefore, unless there’s a good reason not to use it, Metformin deserves real consideration as an initial treatment option for weight management. It could also be used alongside other weight-loss drugs that have the green light from the US Food and Drug Administration. This is especially true when dealing with certain health issues that we’ll get into here.


 Key insights into Metformin’s ability to help people without type 2 diabetes slim down come from two major studies: the Diabetes Prevention Program (DPP) and its extension, the Diabetes Prevention Program Outcomes Study (DPPOS).

In the DPP, which was a carefully designed study involving three groups, researchers looked at how an intensive program for healthy living, a daily dose of 1,700 mg of Metformin, and a dummy pill affected 3,234 individuals who were at risk of developing diabetes. While the main goal was to see if they could prevent or push back the start of type 2 diabetes, they also kept an eye on weight changes. On average, participants weighed about 94.2 kg and had a body mass index (BMI) of 34 when the study began. Over the initial period of nearly three years, those taking Metformin saw an average drop in weight of 2.1 kg. This was less than the lifestyle group, which lost 5.6 kg, but more than the placebo group, which barely saw any change with just a 0.1 kg loss.

Weight loss is maintained

In contrast to those who followed an intensive lifestyle change program, individuals taking Metformin kept their weight off during both the DPP and its follow-up study, DPPOS, which included 2,766 participants. On average, the metformin group saw a sustained weight reduction of about 2.5 kg over time, whereas the lifestyle group gradually put some weight back on, ending up with an average loss of 2.0 kg after a decade.

Around 30% of the people assigned to Metformin dropped more than 5% of their initial body weight within the first year. Further examination revealed that after 15 years, their average weight loss was 6.2% from the starting point, compared to 3.7% for those in the lifestyle group. Sticking to the metformin regimen and losing weight in the first year turned out to be good indicators of keeping the weight off long-term. However, since the DPP and DPPOS weren’t primarily focused on weight loss, we should be careful about how we interpret these findings.

The most extensive look at Metformin’s impact on weight loss as the main goal in non-diabetic individuals is from the early stage of the Biguanides and Prevention of the Risks in Obesity trial. This study involved 324 people with abdominal obesity (selected based on waist-to-hip ratio rather than BMI) who didn’t have diabetes. They were split into two groups, with one receiving 1,700 mg of Metformin daily and the other a placebo. After a year, those on Metformin had a noticeably greater reduction in weight (an average of 2 kg) compared to the placebo group (which lost an average of 0.8 kg), showing that Metformin could indeed make a significant difference.

Higher degrees of insulin resistance

A newer study that wasn’t randomized but took place in a real-life setting looked into how well Metformin worked for weight loss among 154 people with obesity who didn’t have diabetes compared to a group of 45 individuals who didn’t take the medication. Those who took Metformin lost an average of 5.8 kg, while the control group actually gained a little weight, about 0.8 kg on average (P < 0.0001). The more insulin-resistant someone was, as shown by tests like the Matsuda and HOMA indexes, the more weight they tended to lose. This study offers solid evidence of Metformin’s effectiveness in real-world conditions for those with obesity without diabetes. However, it’s worth noting that the control group consisted of people who opted not to use drugs for weight loss, which could introduce some bias in the results.

In a comprehensive review that included 21 studies with 1,004 participants, researchers examined how Metformin affected BMI across various groups. They found that in those with obesity, BMI went down by 1.3 units (weighted mean difference WMD 1.31; 95% CI −2.07 to −0.54). A closer look revealed that Metformin had a stronger impact on individuals with a BMI over 35 kg/m^2 (WMD −1.12; 95% CI −1.84 to −0.39), especially when doses exceeded 1,500 mg/day (WMD −1.01; 95% CI −1.29 to −0.73) and were taken for at least six months (WMD −1.09; 95% CI −1.71 to −0.47).

The findings are mixed when it comes to how quickly you might see weight loss from Metformin. Generally speaking, in studies where patients were followed for longer periods, weight reduction typically began after about four weeks of starting Metformin and mainly occurred within the first 6 to 12 months of ongoing treatment.



During the DPP study, the group that made lifestyle changes saw a 58% drop (95% CI 48% to 66%) in the development of diabetes compared to those who took a placebo. The metformin group also saw a reduction but by 31% (95% CI 17% to 43%). Metformin was especially good at holding off diabetes for people with a higher body mass index (BMI of 35 or more), those under 60 years old, and those who started with higher fasting blood sugar and hemoglobin A1c levels. It was also effective for women who had experienced gestational diabetes before. This protective effect of Metformin has lasted up to 15 years.

Metformin’s benefits extend past helping with weight loss in these particular groups. Its ability to also prevent or delay the start of type 2 diabetes is significant, and its use is recommended not just for managing weight but also as a preventative measure against diabetes.


Weight gain is a common side effect of many antipsychotic medications. Reports indicate that about 75% of individuals taking these drugs see their weight increase by over 7% from their starting weight. Atypical antipsychotics, in particular, are known for leading to more weight gain, with clozapine and olanzapine topping the list, followed by risperidone and quetiapine. There’s a wealth of research on how Metformin can help reduce or reverse weight gain caused by these medications. Yet, it seems that Metformin’s effectiveness isn’t specific to any one antipsychotic drug; rather, it’s the extent of the weight gain that determines how well Metformin works.

Numerous studies have shown that Metformin can be beneficial in counteracting or preventing the weight gain that comes with antipsychotic treatments. A meta-analysis examining 12 studies with 743 participants confirmed Metformin’s effectiveness. On average, those treated with Metformin lost 3.27 kg (95% CI −4.66 to −1.89; Z = 4.64; P < .001) and also saw a significant decrease in BMI (−1.13; 95% CI −1.61 to −0.66) compared to those who took a placebo.

While weight gain is also a concern with other types of medications like certain anticonvulsants, antidepressants, and systemic glucocorticoids, there isn’t enough evidence yet to support the use of Metformin for managing weight in patients using these drugs.

Polycystic ovary syndrome

 Metformin treatment has been found to boost ovulation, regularize menstrual cycles, enhance fertility, and improve the chances of a successful live birth in women who have polycystic ovary syndrome (PCOS). When comparing Orlistat to Metformin for women with PCOS, a meta-analysis observed that both medications had comparable positive impacts on body mass index (BMI). Specifically, there was an average BMI reduction ranging from 3.4 to 4.55 with Metformin and a decrease between 4.48 and 5.7 with Orlistat. The difference was minor, at -0.65%, with a 95% confidence interval of -2.03 to 0.73.


 Some research indicates that Metformin’s ability to reduce body weight goes beyond just making the body more sensitive to insulin. It’s thought that Metformin might also work by:

  • Curbing hunger due to higher levels of hormones like glucagon-like peptide 1 and peptide YY, along with better leptin sensitivity in the brain.
  • Changing the composition of bacteria in the digestive system.
  • Boosting the production and release of growth-differentiating factor 15 can lead to less eating, lower body weight, reduced fasting insulin levels, and improved glucose tolerance.

While most research has focused on the standard, immediate-release version of Metformin, evidence suggests that both the immediate-release and the extended-release forms are equally effective when it comes to weight loss and their influence on hormone secretion.


 When Metformin is prescribed and used correctly, it’s very uncommon to see any serious side effects. The most typical ones involve the digestive system—things like diarrhea, nausea, gas, throwing up, and stomach pain. These side effects tend to happen less often when Metformin is taken with meals and if you’re using the extended-release version rather than the immediate-release one. It’s not yet clear if weight loss from Metformin is due to these gastrointestinal side effects. However, during the Diabetes Prevention Program (DPP), weight loss was closely linked to how well people stuck to their metformin treatment, so it doesn’t seem likely that the two are connected.

The main reason not to use Metformin is if someone has really poor kidney function, specifically an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m^2. For those whose eGFR is between 30 and 60 mL/min/1.73 m^2, the general advice is to lower the dose of Metformin, but there’s no well-established guideline for exactly how much to adjust the dose in clinical trials. If considering Metformin for weight loss in individuals without diabetes, here are some sensible guidelines:

  • Don’t start Metformin if the eGFR is under 45 mL/min/1.73 m^2.
  • If the eGFR is between 45 and 60 mL/min/1.73 m^2, don’t go over a total daily dose of 1,500 mg (or 1,700 mg for the immediate-release form).
  • If the eGFR is between 30 to 45 mL/min/1.73 m^2 and the person is already taking Metformin, limit the dose to a maximum of 1,000 mg per day.

Long-term use of Metformin can lead to lower levels of vitamin B12 in the blood, which has been reported in about 7% of patients. This drop is thought to be because Metformin interferes with how vitamin B12 is absorbed. It’s rare for this to cause anemia, and it seems to be something that can be fixed by stopping Metformin or by taking vitamin B12 supplements—or by doing both.


Metformin is easily accessible and quite affordable, costing roughly $10 for a supply that lasts 90 days. While there haven’t been any investigations into how cost-effective Metformin is specifically for losing weight, an analysis looking at its use to prevent diabetes in the Diabetes Prevention Program (DPP) found that it was either incredibly economical (meaning it led to better results without much extra cost) or it actually saved money (by both enhancing outcomes and cutting down on overall expenses) when compared to a placebo.

Disclaimer and its team members shall not be held responsible for any adverse effects, consequences, or misunderstandings that may arise from the use of Metformin discussed in this article. Users are encouraged to independently verify product information and seek professional medical advice before making any health-related decisions. By reading and relying on this article, users acknowledge and accept that and its team members are not liable for any issues that may arise from the use of Metformin or similar products.


  1. Apolzan JW, Venditti EM, Edelstein SL, et al. Long-term weight loss with metformin or lifestyle intervention in the Diabetes Prevention Program Outcomes study [published correction appears in Ann Intern Med 2020; 173(6):508]. Ann Intern Med 2019; 170(10):682–690. doi:10.7326/M18-1605
  2. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or Metformin. N Engl J Med 2002; 346(6):393–403. doi:10.1056/NEJMoa012512
  3. Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes study [published correction appears in Lancet 2009; 374(9707):2054]. Lancet 2009; 374(9702): 1677–1686. doi:10.1016/S0140-6736(09)61457-4
  4. Fontbonne A, Charles MA, Juhan-Vague I, et al. The effect of Metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care 1996; 19(9):920–926. doi:10.2337/diacare.19.9.920
  5. Seifarth C, Schehler B, Schneider HJ. Effectiveness of Metformin on weight loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes 2013; 121(1):27–31. doi:10.1055/s-0032-1327734
  6. Pu R, Shi D, Gan T, et al. Effects of Metformin in obesity treatment in different populations: a meta-analysis. Ther Adv Endocrinol Metab 2020; 11:2042018820926000. doi:10.1177/2042018820926000
  7. Lawson AA, Strong JA, Peattie P, Roscoe P, Gibson A. Comparison of fenfluramine and Metformin in treatment of obesity. Lancet 1970; 2(7670):437–441. doi:10.1016/s0140-6736(70)90056-5
  8. Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res 1998; 6(1):47–53. doi:10.1002/j.1550-8528.1998.tb00314.x
  9. Diabetes Prevention Program Research Group. Long-term effects of Metformin on diabetes prevention: identification of subgroups that benefited most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes study. Diabetes Care 2019; 42(4):601–608. doi:10.2337/dc18-1970
  10. Ratner RE, Christophi CA, Metzger BE, et al. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab 2008; 93(12):4774–4779. doi:10.1210/jc.2008-0772
  11. Wu RR, Zhao JP, Jin H, et al. Lifestyle intervention and Metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 2008; 299(2):185–193. doi:10.1001/jama.2007.56-b
  12. de Silva VA, Suraweera C, Ratnatunga SS, Dayabandara M, Wanniarachchi N, Hanwella R. Metformin in preventing and treating antipsy-chotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry 2016; 16(1):341. doi:10.1186/s12888-016-1049-5
  13. Graff SK, Mario FM, Ziegelmann P, Spritzer PM. Effects of Orlistat vs Metformin on weight loss-related clinical variables in women with PCOS: systematic review and meta-analysis. Int J Clin Pract 2016; 70(6):450–461. doi:10.1111/ijcp.12787
  14. Yerevanian A, Soukas AA. Metformin: mechanisms in human obesity and weight loss. Curr Obes Rep 2019; 8(2):156–164. doi:10.1007/s13679-019-00335-3
  15. Day EA, Ford RJ, Smith BK, et al. Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss. Nat Metab 2019; 1(12):1202–1208. doi:10.1038/s42255-019-0146-4
  16. Derosa G, Carbone A, Franzetti I, et al. Effects of a combination of sitagliptin plus Metformin vs. metformin monotherapy on glycemic control, β-cell function, and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract 2012; 98(1):51–60. doi:10.1016/j.diabres.2012.05.022
  17. Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with Metformin in the Diabetes Prevention Program Outcomes study. Diabetes Care 2012; 35(4):731–737. doi:10.2337/dc11-1299
  18. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 2014; 312(24):2668–2675. doi:10.1001/jama.2014.15298
  19. Herman WH. The cost-effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes study. Clin Diabetes Endocrinol 2015; 1:9. doi:10.1186/s40842-015-0009-1

Read also:

You cannot copy content of this page